© 2026 Sinochem Nanjing Corporation,
All Right Reserved
In the world of antiviral breakthroughs, zidovudine’s legacy stretches back to the feverish hunt for answers during the AIDS crisis of the 1980s. Developed initially in the 1960s at the Michigan Cancer Foundation for its anticancer promise, researchers saw it collect dust as an unremarkable project until a hasty re-examination against HIV changed everything. It shot to prominence in 1987, earning FDA approval as the first antiretroviral drug, commonly known as AZT. This wasn’t just a scientist’s pen-to-paper moment; it meant hope tangibly arrived for thousands living under the uncertainty of HIV. Clinicians still remember the seismic feeling when the data showed that this chemical, long forgotten, could stall viral replication. Its approval unfolded rapidly, not only underlining the urgency that shaped the decade but also laying the groundwork for all future progress in HIV medicine.
Zidovudine comes as an oral tablet, capsule, and syrup, as well as an intravenous solution for those needing hospital-based care. The pharmaceutical forms contain the active ingredient, supported often by simple pharmaceutical fillers—cellulose, magnesium stearate, and sometimes sodium starch glycolate to ensure stability and absorption. Zidovudine presents itself in strengths of 100mg, 250mg, and 300mg tablets, with syrup concentrations aimed at pediatric and specialized care. Marketed under names like Retrovir, it captures a range of formulations both in originator and generic guise, across nearly every country fighting HIV. Packaging carries clear warnings about storage needs—room temperature, away from light, and indispensable safety labeling about short expiry dates compared to some other meds.
Zidovudine appears as an off-white, crystalline powder with a melting point sitting just shy of 127°C. Its faint solubility in water invites formulation challenges, driving pharmaceutical companies to continually tweak excipients for more predictable absorption. Chemically, it identifies as a thymidine analog, so its backbone mixed with nitrogens reflects the body’s own building blocks of DNA. C10H13N5O4, its molecular formula, brings a molecular weight approaching 267 g/mol. The molecule’s UV absorption peaks near 267 nm, a standard trait for nucleoside analogues, which helps labs rapidly identify its presence in biological samples or confirm product purity. Zidovudine stands up to acidic pH but quickly shows signs of degradation when suspended in ultrabasic solutions or exposed to intense UV light—vulnerabilities not just to be noted by pharmacists but by researchers exploring new combinations.
Labeling for zidovudine must spell out storage, dosing, and explicit warnings about potential toxicity. Every bottle or blister lists batch numbers and expiration dates given its tendency to break down. Packaging for both professional and patient use must carry risk information, especially about anemia and neutropenia flagged by red cell and white cell changes. Fact sheets accompanying each product version go into detail about co-administration with other antiretrovirals, watching for resistance patterns and cross-reactivity especially in combination drug formulations designed for people who cannot swallow multiple pills.
Making zidovudine isn’t a kitchen table process—it unfolds through multistep organic synthesis. Starting from thymidine, chemists swap its 3’-hydroxyl group for an azido (-N3) group through reaction with sodium azide, typically following tritylation and mesylation steps. The process relies on meticulous temperature and humidity control because intermediates break down easily, robbing yield. Even today, the method continues to fuel research as teams worldwide look for greener synthesis routes with fewer waste byproducts. Some labs have experimented with enzymatic synthesis or flow chemistry, battling not just for efficiency but for cost control as low- and middle-income countries fight to secure sustainable drug access.
Zidovudine’s chemical reactivity centers around its azido group, making it a candidate for further modifications—both in academic research and for tweaking pharmacological behavior. Researchers have swapped the azido group for amines or other nucleophiles in attempts to tune toxicity or resistance profiles. It stands as a starting point for prodrugs and delivery vehicles, with acylation at the 5’-OH group producing forms that release zidovudine more slowly, aiming to decrease dosing frequency and blunt toxicity. People working in novel drug delivery, like nanoparticles or long-acting depot shots, keep zidovudine’s core structure in constant mutation, always with an eye to outflanking viral resistance or sidestepping blood cell suppression.
Zidovudine answers to different names—Retrovir, AZT, and in some countries, ZDV or Zidovir. International drug listings show synonyms like azidothymidine, and pharmacies keep it under a cross-reference list because hospital formularies might not standardize on a single name. Researchers know to crosscheck studies, because one group might call out AZT and another sticks with ZDV, but the molecule remains constant. It wears enough labels that one must pay attention in global collaboration, especially as generic versions came online, chipping away at the original’s patent-protected pricing and broadening patient access.
Handling zidovudine in research or production settings involves gloves, fume hoods, and eye protection—standard lab fare, but given its cytotoxic potential, not to be shrugged off. Workers avoid inhaling powder or skin contact, with cleanup procedures for spills including proper hazardous waste disposal. Healthcare settings face similar care; intravenous formulations demand careful dilution and immediate use because of contamination and degradation risks. Practitioners remain alert for side effects, especially rapid declines in red or white blood cell counts, and adjust doses with real-time bloodwork. Even pharmacy teams focus training on counseling about missed doses and avoidance of abrupt discontinuation, given the risk of viral rebound.
Clinicians turn to zidovudine most in combination antiretroviral therapy—ART, the lifeline for people living with HIV. It played a unique role in mother-to-child transmission prevention, with early studies showing that maternal and neonatal dosing cut infection rates from 25% to less than 8%. It pops up in post-exposure prophylaxis kits for healthcare worker needle sticks and continues to punch above its weight in many global treatment guidelines, despite newer options landing with improved side effect profiles. Its historical use charts not just the rise of combination therapy, but also the democratization of HIV care as patent expiration and generic versions enabled international campaigns targeting the virus.
Despite younger cousins like tenofovir and integrase strand inhibitors stealing the limelight, research into zidovudine marches on. Teams work on formulations blending zidovudine into fixed-dose combination tablets—one pill covering multiple drug actions for easier adherence. There’s fresh interest in targeting latent reservoirs of HIV—hiding cells that evade traditional therapy—and zidovudine modifications sometimes get a ticket back into the lab for tests in novel delivery systems like implantable pellets or slow-release gels. Researchers also care deeply about resistance; even as viral resistance to zidovudine gained attention, new combinations and modifications attempt to outpace HIV’s slippery evolution.
Zidovudine’s toxicity profile keeps both providers and researchers on their toes. Chronic dosing risks bone marrow suppression, leading to anemia and neutropenia in a significant slice of patients—one reason regular blood monitoring remains routine. Elevated liver enzymes, muscle pain, and rare but serious lactic acidosis show up in the literature and patient stories alike. Animal studies revealed reproductive toxicity at high doses; long-term outcomes for children exposed in pregnancy remain a monitoring focus in public health. This has kept the scientific community scanning for modifications that could blunt toxicity without snuffing out antiviral punch. Health agencies worldwide, including the WHO, keep updating guidelines as new safety and toxicity data pours in.
The journey for zidovudine doesn’t freeze in time, even as science invents new molecules. With the global scale-up of combination ART, generic manufacturers still invest heavily in production, especially for applications where price, long shelf life, and proven safety outshine the allure of newer but costlier drugs. There’s movement to further optimize pediatric formulations—more stable suspensions, dispersible tablets, and palatable syrups. Some research explores its usage outside of HIV, for example in the treatment of Human T-cell Leukemia Virus. In low- and middle-income countries, zidovudine endures because it delivers results at a price many public health budgets can touch. Its dual legacy—trailblazer of antiviral therapy and cornerstone of ongoing access—keeps it in focus. Whether handed to a mother laboring to give her child a virus-free start or as part of daily routine for someone living with HIV, zidovudine’s story continues as a reminder that science, sometimes, circles back to its beginnings for new solutions.
AIDS hit hard in the 1980s. People searched for answers, while fear took over many conversations. Doctors needed a real treatment option, and zidovudine — often called AZT — became the first drug to offer hope. Scientists originally developed it decades earlier as a possible cancer therapy, but it found new purpose after researchers discovered how it blocked HIV’s ability to multiply.
HIV attacks the immune system by inserting itself into human DNA. Zidovudine gets in the way by tricking the virus. The drug looks almost like the building blocks HIV uses to copy itself. Once HIV takes the bait, zidovudine halts the copying process, stopping the next wave of infection inside the body. While today’s treatments usually mix several drugs in one pill, zidovudine kicked off the modern era of antiretroviral therapy.
I’ve talked with people who lived through those early years. Before zidovudine, an HIV diagnosis almost always meant preparing for the worst. The first reports showing people living longer after starting the drug sent ripples of optimism through hospitals and affected communities. Zidovudine didn’t cure HIV, but it turned the tide, transforming the disease into something that could be managed rather than feared as certain death.
Doctors now typically use zidovudine as one part of a combination—never alone. Using just one medication gave HIV a chance to outsmart treatment by mutating. Combining three or more drugs lowered the risk of resistance. Still, zidovudine remains useful, especially when newer drug combinations aren’t available, or during special situations like preventing mother-to-child HIV transmission during birth. Studies show that zidovudine, given to pregnant women with HIV and their newborns, slashes the risk of the virus spreading to babies.
Zidovudine isn’t without drawbacks. People on zidovudine can experience side effects such as anemia or stomach problems. This reminds us no drug brings a perfect solution—there’s always a trade-off between benefits and risks. Still, for some people in lower-income countries, zidovudine forms a lifeline when cost or access shuts the door on newer treatments. The World Health Organization has kept zidovudine on its list of essential medicines for that reason.
Public health experts highlight the value of testing early and getting medicines started quickly. Delaying treatment leads to more illness and raises the chance of passing HIV on to others. Lessons from zidovudine’s story are still useful today. We all gain when research moves beyond a single breakthrough to build stronger, safer, and more accessible treatment for everyone. Modern medicine stands on the shoulders of older drugs like zidovudine, and the hard-earned victories against stigma and silence push further progress on all fronts.
Zidovudine, known to many as AZT, lines up as one of the earliest antiretroviral medications used to treat HIV. Decades of use put a spotlight on its effectiveness, but the book on side effects grew thick pretty quickly. As someone who has seen patients fight both the virus and the side effects, I can tell you: this drug brings some predictable issues to the table.
People using zidovudine often feel drained or run down. This isn't just about staying up too late or a bad night’s sleep. Zidovudine lowers the bone marrow's drive, which means red blood cells take a hit. Fewer red blood cells turns into a condition called anemia. This leaves folks feeling tired, weak, or short of breath after a short walk. Doctors caught on to this issue pretty early, so blood count checks remain a staple for anyone on AZT.
Upset stomach comes up a lot among zidovudine users. Nausea and vomiting start early for some and stick around longer than anyone would like. Food might not taste right anymore. A meal that once was a favorite can trigger a wave of queasiness. Even mild appetite loss—if it drags on—can pull down a body that’s already stretched thin fighting a virus.
People sitting across from me years ago would complain about pounding headaches and restless nights. A buzzing head combined with patchy sleep wears anyone down. Over-the-counter pain relievers, a quiet bedroom, less caffeine—most people try every trick to get through it. Sticking to a set routine before bed can help, but for some, the discomfort lingers.
AZT can spark muscle aches and weakness. Some describe it as feeling sore after a full day of physical labor even when they hardly left the couch. A long course on zidovudine sometimes causes a specific problem called myopathy—muscle damage that needs close attention.
White blood cells, the body’s defenders, sometimes fall to lower levels with ongoing zidovudine. People notice more colds that seem to hang around or unexpected infections. Regular blood checkups let providers catch dropping counts before real trouble starts.
Zidovudine carries a rare but real risk: lactic acidosis. This dangerous buildup of lactic acid in the body can trigger deep muscle pain, belly aches, fast breathing, or even confusion. The liver can also become inflamed (hepatomegaly) or stop working as it should. I have met people who brushed off early warning signs, only to face serious complications later. Paying close attention when fatigue feels out of proportion, or when unexplained symptoms appear, can catch problems in time.
Open conversations with care teams matter. If symptoms like tiredness, nausea, or pain flare up, talking about it early can prompt a switch to a newer medication. Today’s therapies usually work just as well—or better—without many of the same burdens. Trusted sources like the National Institutes of Health and World Health Organization provide updated guidelines, and people living with HIV deserve tailored care based on real experiences, not just statistics.
Regular bloodwork, good nutrition, and honest feedback to clinicians shape the future of treatment. Medicine keeps moving forward, but staying alert to old and new side effects steers people toward better health every day.
Zidovudine, often called AZT, helps control HIV infection. Back in the 1980s, when HIV treatment options looked pretty limited, zidovudine brought new hope to people who worried about their health every day. Fast forward to now, doctors usually combine it with other medicines as part of antiretroviral therapy. Taking it right makes the difference between managing HIV well or facing unwanted problems.
Life rarely slows down for anyone living with a tough diagnosis. Zidovudine has to stay in the bloodstream, so missing doses lets the virus gain ground, and that’s trouble from what I’ve seen in clinics, both in worried patients and in the stories that stick. So, sticking to the schedule feels almost like respecting a strict coach: twice each day, usually every 12 hours, with or without food. Some try skipping meals or tossing down the medicine between meetings—most regret that decision because upset stomach, headache, and even nausea can hit harder when routines get sloppy.
Doctors always stress reading the label, but real life tests even the best intentions. I remember one patient, stressed from juggling parenting and work, who found that pairing her dose with breakfast and dinner made it foolproof. No missed pills. No running to the pharmacy begging for refills after finishing early. Physical reminders help. Alarms on a phone, pill organizers from the drugstore, or a friendly nudge from a partner all add up. No app replaces real accountability.
Chasing down zidovudine with soda doesn’t sit well. Water works best—it avoids stomach irritation and cuts down on heartburn. Some people like swallowing capsules, some prefer liquid, especially if pills feel impossible. Liquid works just as well as tablets, but checking the dosage carefully with the measuring spoon from the pharmacist matters. Sometimes caretakers or families think eyeballing liquids is fine, but a little over or under does change results.
Side effects always loom in the background. I’ve watched someone chalk up tiredness and muscle aches to an overbooked week, when really, low red blood cells from zidovudine was the hidden culprit. Keeping track of headaches, fatigue, or even lighter side effects like minor rashes opens the door for action. Regular blood work at the doctor’s office, even when everything feels fine, keeps things on track.
Community groups and health educators constantly repeat this message: skipping doses not only weakens general health, but lets HIV learn new tricks. Drug resistance sneaks in before you feel it. Sticking to the plan keeps other drugs working and backs up all that effort. For families and caregivers, supporting the routine brings a sense of teamwork. One person’s commitment ripples out—helping kids stay healthy, partners worry less, and future plans feel more solid.
Doctors, nurses, and pharmacists all want honest questions—no one expects you to remember every instruction. If side effects linger, or if a work schedule makes dosing hard, plenty of options exist to smooth out the process. Self-advocacy never comes easy at the start, but confidence grows, and so does the support network. Zidovudine doesn’t solve everything, but with steady hands and honest questions, it steers things in a better direction.
Zidovudine, known by many as AZT, changed the game for people living with HIV back in the late 1980s. Researchers realized pretty early on that it didn’t just help HIV-positive folks themselves; it could cut down the risk of a mom passing the virus to her child. This caught my attention years ago during a shadowing stint in an urban clinic, where doctors had tough conversations about HIV every day with soon-to-be mothers. Expectant women in those crowded waiting rooms often asked straight up: “Will this medicine hurt my baby?”
The fear doesn’t come from nowhere—many people still carry fresh memories of medications gone wrong during pregnancy. But Zidovudine comes backed by decades of real-world experience. Big studies from the U.S. and Europe show that using this medication, along with other antiretrovirals, brings the chance of mother-to-child HIV transmission down to less than 1%. Women getting treatment carry less virus in their blood, which lowers what passes to the baby during pregnancy or delivery. I sat in on visits where mothers left with actual hope after hearing numbers like that.
Medical guidelines from WHO and CDC both put Zidovudine on their short list for pregnancy. It’s no secret—HIV specialists reach for it all the time. But people stay anxious about side effects. Zidovudine has been linked to anemia—low red blood cells. Moms visit the lab more often to stay on top of that one. Babies can feel the effects, too. Most side effects remain mild and show up in a minority, but it’s something I’ve watched nurses stress over every few months when patients come in for blood draws. Doctors also sometimes switch drugs if side effects pile up.
There’s no storybook ending for every case. Some research points to Zidovudine possibly causing minor birth defects or affecting growth in a small percentage of infants, but these links aren’t solid. Medical teams weigh the risks and make a plan with each mom. More than once, I’ve seen doctors bring the actual study numbers to the exam room. Seeing the research—real charts, not rumor—helps patients make peace with the choice.
A lot of expectant mothers don’t start prenatal care early. Long work hours, childcare issues, or plain old fear keep people away. HIV can fly under the radar for months. Zidovudine does its best work when started early, so more public health programs have started chasing down missed appointments and knocking on doors. Community health workers, who sometimes live on the same block as their patients, talk about Zidovudine in terms people relate to: keeping babies healthy, giving families a shot at normal life.
Cost sometimes stands in the way. Generic Zidovudine isn’t as expensive as it once was, but not everywhere offers it for free. Insurance battles still drag out. What helps most is government funding and clinics that push for coverage. Grassroots advocacy—real people writing and calling lawmakers—make all the difference in getting these meds on formularies.
Zidovudine brings hope to families facing HIV. Sticking with antenatal visits, clear communication between care teams, and tackling obstacles head-on make the road smoother for moms and babies. What I learned from families is that trust—earned in a small office or a big public clinic—turns a scary diagnosis and a bottle of pills into a lifeline. Advancing new research and keeping treatment affordable will mean more healthy kids get to head home, HIV free, from the delivery floor.
Zidovudine turned the tide for many living with HIV. It helped keep the virus in check and offered hope during a time when treatment options felt limited. People rely on it as part of combination regimens. With any medication that packs a punch, questions come up about mixing it with other prescriptions or over-the-counter remedies.
Zidovudine doesn’t operate in a bubble. I’ve seen people frustrated when their symptoms take a turn after adding a new drug to their regimen. Food rarely changes how zidovudine behaves, but other medicines can tip the balance, sometimes making side effects worse or raising the risk for complications.
Most people taking zidovudine already use more than one antiretroviral. Combining it with drugs like stavudine doesn’t work out; they wind up fighting for the same binding spots in the virus, and one cancels out the other. Lamivudine and abacavir, on the other hand, work well beside zidovudine, and doctors often recommend those combinations to strengthen HIV defense.
Certain antibiotics can create trouble. Rifampin speeds up the body’s removal of zidovudine, making it less effective. One moment, lab results show the drug doing its job, the next, levels drop after rifampin starts up. Fluconazole, an antifungal, has the opposite effect and can actually raise zidovudine levels. Anyone dealing with a serious infection needs real-time communication with their healthcare team and access to frequent checkups and lab work.
Doctors prescribe paracetamol (acetaminophen) for pain, but high doses or long-term use can stress the liver. Zidovudine also pushes the liver. Taken together, the risk for liver issues spikes. Ibuprofen and aspirin don’t show the same impact, but it still pays off to keep a close eye, especially in people who have lived with HIV for a long time or already struggle with liver disease.
It’s easy to overlook vitamins and herbal supplements, but they can change how drugs work. St. John’s wort, in particular, revs up liver enzymes and makes zidovudine less effective. People think because something came from a plant, it’s harmless. Reality doesn’t always match up. Checking labels isn’t enough—people need a real conversation with doctors or pharmacists about everything in their daily routine.
Pharmacies and clinics play a frontline role. I remember patients dropping off bags full of bottles, worried about forgetting what each does or how they interact. Keeping medication lists updated and sharing those with every care provider makes a difference. Offering clear, judgment-free advice removes barriers. More resources—like medication management apps and pharmacist check-ins—give people extra support. Sharing trusted resources, such as NIH’s guidelines or local HIV support groups, gives patients power to spot issues early.
Too many people feel brushed aside when they ask about drug interactions or report side effects. Patients deserve time, careful listening, and easy-to-understand explanations. Medical teams working together—doctors, pharmacists, nurses—create stronger safety nets for everyone taking zidovudine. Better public information and easier access to up-to-date interaction checkers put tools in the hands of the people who need them most.
References: 1. U.S. National Institutes of Health HIVinfo.2. Clinical practice and firsthand observation in community pharmacy settings. 3. Peer-reviewed literature on zidovudine and drug interactions.
| Names | |
| Preferred IUPAC name | 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2,4-dione |
| Other names |
AZT Retrovir ZDV |
| Pronunciation | /zaɪˈdoʊvjʊˌdiːn/ |
| Identifiers | |
| CAS Number | 30516-87-1 |
| Beilstein Reference | 1721847 |
| ChEBI | CHEBI:10110 |
| ChEMBL | CHEMBL44638 |
| ChemSpider | 1843 |
| DrugBank | DB00495 |
| ECHA InfoCard | ECHA InfoCard: 100.064.783 |
| EC Number | 2.7.1.6 |
| Gmelin Reference | 766393 |
| KEGG | D00493 |
| MeSH | D015215 |
| PubChem CID | 35370 |
| RTECS number | YZ3150000 |
| UNII | M9M6Y8Y879 |
| UN number | UN3248 |
| Properties | |
| Chemical formula | C10H13N5O4 |
| Molar mass | 267.24 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.335 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 0.05 |
| Vapor pressure | 8.2E-7 mmHg at 25°C |
| Acidity (pKa) | pKa = 9.68 |
| Basicity (pKb) | 12.19 |
| Magnetic susceptibility (χ) | -74.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.64 |
| Dipole moment | 5.7093 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 263.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -206.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -7048 kJ/mol |
| Pharmacology | |
| ATC code | J05AF01 |
| Hazards | |
| Main hazards | May cause cancer, heritable genetic damage, and harm to unborn child. |
| GHS labelling | GHS02, GHS07, GHS08 |
| Pictograms | 🧬💊🤰🚫 |
| Signal word | Warning |
| Hazard statements | H350: May cause cancer. |
| Precautionary statements | P201, P202, P264, P270, P280, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | 153.8°C |
| Autoignition temperature | 160°C |
| Lethal dose or concentration | LD50 (oral, rat): 3.6 g/kg |
| LD50 (median dose) | LD50 (median dose) of Zidovudine: **3.6 g/kg (oral, mouse)** |
| NIOSH | AS0183000 |
| PEL (Permissible) | PEL (Permissible) of Zidovudine: 0.1 mg/m³ |
| REL (Recommended) | 300 mg every 12 hours |
| IDLH (Immediate danger) | NIOSH: Not Listed |
| Related compounds | |
| Related compounds |
Thymidine Stavudine Azidothymidine triphosphate |
